BHVN

BiohavenA

NYSE / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

25%

Probability

Target price

$24.00

Analysis reference price unavailable

Analysis 2026-08-06 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$14.50

Analysis reference price unavailable

Analysis 2026-08-06 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$9.00

Analysis reference price unavailable

Analysis 2026-08-06 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-08-06

AI commentary

News tone is mixed: clinical milestones support optionality, while leadership changes and the absence of verified Q2 earnings follow-up limit confidence. The stock anchor is $13.63 as of 2026-08-05. Social coverage, options data, short interest, employee sentiment, analyst revisions, and a clean post-earnings reaction attribution are unavailable; this remains a cautious monitoring setup.

RankAlpha Sentiment Codex - 2026-08-06

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-08-06catalystQ2 2026 earnings confirmation remains an evidence gapMedium impact

No verified Q2 2026 EPS, revenue, guidance change, transcript, or company earnings release was available in the packet or checked sources as of 2026-08-06. The latest usable earnings source is the Q1 SEC 8-K, which highlighted upcoming clinical milestones [#SEC-8K-2026-05-04].

2026-11-04eventOpakalim pivotal epilepsy dataHigh impact

Biohaven expects topline results from its pivotal opakalim epilepsy program in the second half of 2026, creating a binary validation point for a late-stage asset [#SEC-8K-2026-05-04].

2026-11-04eventTaldefgrobep obesity topline dataHigh impact

The Phase 2 taldefgrobep alfa obesity study completed enrollment, with topline data expected in the second half of 2026 [#SEC-SEC-8K-2026-05-04].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-08-06 • Updated nightlySource: Internal modelMethodology